Skip Navigation

Lotus Reported Unaudited October Consolidated Revenues of NT$912 million, Marking a Nearly 10% YoY Growth Accumulated Unaudited Consolidated Revenue for the Frist Ten Months Recorded NT$14.45 billion, with 17.58% YoY Growth

10 November 2023

Taipei, Taiwan, November 10, 2023 — Lotus Pharmaceutical Co., Ltd. (Listed on the Taiwan Stock Exchange as: 1795), a prominent international pharmaceutical company headquartered in Taiwan, announces its unaudited combined revenue for October 2023, which amounts to NT$912 million. This represents a growth of 9.93% compared to the corresponding period last year. The company's year-to-date combined revenue now stands at NT$14.45 billion, reflecting an increase of 17.58% when compared to the first ten months of the previous year. Notably, Lotus has nearly matched its entire revenue for the full year of 2022 within just the first ten months of this year.

Both the Asian and export sectors have demonstrated growth this month compared to the same period in the previous year. Asian operations experienced approximately 6% growth, while global exports grew by around 28% year-on-year. As has been the case in previous years, the delivery of Buprenorphine/Naloxone was lower this month due to manufacturing scheduling. Nevertheless, Buprenorphine/Naloxone, the generic equivalent of Suboxone®, has maintained its strong presence in the US market, achieving a robust year-on-year revenue growth of 23% during the first three quarters of 2023. We anticipate continued strong demand for Buprenorphine/Naloxone in the fourth quarter.

In October, Lotus continued its drive to secure significant approvals for its oncology product line on a global scale. Notably, Vinorelbine 30mg received its final regulatory clearance in Vietnam, marking the third strength approval following the 20mg and 80mg strengths approved earlier this year. Tegafur/Gimeracil/Oteracil Potassium 20mg and 25mg, used for gastric cancer treatment, obtained regulatory approvals in Hong Kong. Furthermore, Gefitinib 250mg was granted approval in Colombia, and Pazopanib 200mg received regulatory clearance in South Africa.

Lotus Pharmaceutical remains dedicated to its mission of evolving from a local Taiwanese generic pharmaceutical company into a global pharmaceutical platform with a diverse product portfolio encompassing generic drugs, branded drugs, NCEs, and 505(b)(2) products.


About Lotus

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.



Media Enquiries:

Susan Liao, IR/PR Director

+886 2 2700 5908